Although previous studies showed that the presence of a de novo T790M mutation was associated with worse progression‐free survival (PFS) and overall survival (OS) in patients with advanced EGFRm+ NSCLC treated with 1G16, 22, 23, 24 and 2G25, 26 EGFR‐TKIs, most of these studies were performed prior to the development of osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.